Novavax Inc (NVAX)

[PH4RM4C3UT1C4LS]

86,000 shares were bought by Rachel King (Director) on 3/27/19, at a price of $ 0.53. Could be telling of the upside....

Interested to see how these conferences/talks go the next few weeks.

I tend to think NVAX will get approval on the secondary endpoints for the RSV vaccine, but will need some post-marketing data to validate. RSV is a very serious condition in these infants, and preventing the most serious complications is a huge stride in the right direction.

For NanoFlu, yes they will need further funding, but I see no reason why the data will not turn out positive. I believe that these conferences will secure funding, or interest in a partnership/buyout.